Oral tyrosine kinase inhibitor tablets targeting EGFR mutations in non-small cell lung cancer. Distributed by pharma suppliers to specialized oncology pharmacies and hospital procurement for outpatient and inpatient use by medical oncologists in targeted therapy regimens.